We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

1ttm

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1ttm.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1ttm.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1ttm| PDB=1ttm | SCENE= }}
{{STRUCTURE_1ttm| PDB=1ttm | SCENE= }}
-
'''Human carbonic anhydrase II complexed with 667-coumate'''
+
===Human carbonic anhydrase II complexed with 667-coumate===
-
==Overview==
+
<!--
-
CA (carbonic anhydrase) catalyses the reversible hydration of carbon dioxide into bicarbonate, and at least 14 isoforms have been identified in vertebrates. The role of CA type II in maintaining the fluid and pH balance has made it an attractive drug target for the treatment of glaucoma and cancer. 667-coumate is a potent inhibitor of the novel oncology target steroid sulphatase and is currently in Phase 1 clinical trials for hormone-dependent breast cancer. It also inhibits CA II in vitro. In the present study, CA II was crystallized with 667-coumate and the structure was determined by X-ray crystallography at 1.95 A (1 A=0.1 nm) resolution. The structure reported here is the first for an inhibitor based on a coumarin ring and shows ligation of the sulphamate group to the active-site zinc at 2.15 A through a nitrogen anion. The first two rings of the coumarin moiety are bound within the hydrophobic binding site of CA II. Important residues contributing to binding include Val-121, Phe-131, Val-135, Leu-141, Leu-198 and Pro-202. The third seven-membered ring is more mobile and is located in the channel leading to the surface of the enzyme. Pharmacokinetic studies show enhanced stability of 667-coumate in vivo and this has been ascribed to binding of CA II in erythrocytes. This result provides a structural basis for the stabilization and long half-life of 667-coumate in blood compared with its rapid disappearance in plasma, and suggests that reversible binding of inhibitors to CA may be a general method of delivering this type of labile drug.
+
The line below this paragraph, {{ABSTRACT_PUBMED_15453828}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 15453828 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_15453828}}
==Disease==
==Disease==
Line 39: Line 43:
[[Category: Obesity]]
[[Category: Obesity]]
[[Category: Steroid sulfatase inhibitor]]
[[Category: Steroid sulfatase inhibitor]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 10:20:51 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 10:14:44 2008''

Revision as of 07:14, 28 July 2008

Image:1ttm.png

Template:STRUCTURE 1ttm

Contents

Human carbonic anhydrase II complexed with 667-coumate

Template:ABSTRACT PUBMED 15453828

Disease

Known disease associated with this structure: Osteopetrosis, autosomal recessive 3, with renal tubular acidosis OMIM:[611492]

About this Structure

1TTM is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent., Lloyd MD, Pederick RL, Natesh R, Woo LW, Purohit A, Reed MJ, Acharya KR, Potter BV, Biochem J. 2005 Feb 1;385(Pt 3):715-20. PMID:15453828

Page seeded by OCA on Mon Jul 28 10:14:44 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1ttm"
Personal tools